The insulin-suppressive effect of resveratrol - An in vitro and in vivo phenomenon

Life Sciences

Volumn 82, Issue 7-8, 2008, Pages 430-435

  Szkudelski, Tomasz ^a  

^a POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Insulin secretion; Insulinemia; Pancreatic islets; Resveratrol

Indexed keywords

ACETYLCHOLINE; PROTEIN KINASE C; RESVERATROL; SOMATOSTATIN RECEPTOR; SUCCINIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS ISLET;

ACETYLCHOLINE; ANIMALS; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG COMBINATIONS; ENZYME ACTIVATION; GLUCOSE; INSULIN; ISLETS OF LANGERHANS; MALE; ORGAN CULTURE TECHNIQUES; PROTEIN KINASE C; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; STILBENES; SUCCINIC ACID;

RATTUS;

EID: 39149108101     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.12.008     Document Type: Article

References (40)

1. Alemzadeh R., Fledelius C., Bodvarsdottir T., and Sturis J. Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. Metabolism 53 4 (2004) 441-447
2. Atten M.J., Attar B.M., Milson T., and Holian O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochemical Pharmacology 62 10 (2001) 1423-1432
3. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., and Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 7117 (2006) 337-342
4. Bergmeyer H.U., and Bernt E. D-glucose determination with glucose oxidase and peroxidase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1974), Academic Press, New York 1205-1215
5. Björk E., Berne C., Kämpe O., Wibell L., Oskarsson P., and Karlsson F.A. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45 10 (1996) 1427-1430
6. Chen W.P., Chi T.C., Chuang L.M., and Su M.J. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. European Journal of Pharmacology 568 1-3 (2007) 269-277
7. Chi T.C., Chen W.P., Chi T.L., Kuo T.F., Lee S.S., Cheng J.T., and Su M.J. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sciences 80 18 (2007) 1713-1720
8. Cosgrove K.E., Antoine M.H., Lee A.T., Barnes P.D., de Tullio P., Clayton P., McCloy R., De Lonlay P., Nihoul-Fékété C., Robert J.J., Saudubray J.M., Rahier J., Lindley K.J., Hussain K., Aynsley-Green A., Pirotte B., Lebrun P., and Dunne M.J. BPDZ 154 activates adenosine 5′-triphosphate-sensitive potassium channels: in vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism. Journal of Clinical Endocrinology and Metabolism 87 11 (2002) 4860-4868
9. Fahien L.A., and MacDonald M.J. The succinate mechanism of insulin release. Diabetes 51 9 (2002) 2669-2676
10. Greenwood R.H., Mahler R.F., and Hales C.N. Improvement in insulin secretion in diabetes after diazoxide. Lancet 28 7957 (1976) 444-447
11. Guldstrand M., Grill V., Björklund A., Lins P.E., and Adamson U. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes and Metabolism 28 6 (2002) 448-456
12. Hambrock A., de Oliveira Franz C.B., Hiller S., Grenz A., Ackermann S., Schulze D.U., Drews G., and Osswald H. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. Journal of Biological Chemistry 282 5 (2007) 3347-3356
13. Hansen J.B., Arkhammar P.O., Bodvarsdottir T.B., and Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Current Medicinal Chemistry 11 12 (2004) 1595-1615
14. Hebbar V., Shen G., Hu R., Kim B.R., Chen C., Korytko P.J., Crowell J.A., Levine B.S., and Kong A.N. Toxicogenomics of resveratrol in rat liver. Life Sciences 76 20 (2005) 2299-2314
15. Juan M.E., Buenafuente J., Casals I., and Planas J.M. Plasmatic levels of trans-resveratrol in rats. Food Research International 35 (2002) 195-199
16. Kane C., Lindley K.J., Johnson P.R., James R.F., Milla P.J., Aynsley-Green A., and Dunne M.J. Therapy for persistent hyperinsulinemic hypoglycemia of infancy. Understanding the responsiveness of beta cells to diazoxide and somatostatin. Journal of Clinical Investations 100 (7) (1997) 1888-1893
17. Lacy P.E., and Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16 1 (1967) 35-39
18. Laedtke T., Kjems L., Pørksen N., Schmitz O., Veldhuis J., Kao P.C., and Butler P.C. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. American Journal of Physiology: Endocrinology and Metabolism 279 3 (2000) 520-528
19. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 6 (2006) 1109-1122
20. Leahy J.L., Bumbalo L.M., and Chen C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 43 2 (1994) 173-179
21. Leiro J., Alvarez E., Garcia D., and Orallo F. Resveratrol modulates rat macrophage functions. International Immunopharmacology 2 6 (2002) 767-774
22. Matsuda M., Kawasaki F., Mikami Y., Takeuchi Y., Saito M., Eto M., and Kaku K. Rescue of beta-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes. European Journal of Pharmacology 453 1 (2002) 141-148
23. Meissner T., Brune W., and Mayatepek E. Persistent hyperinsulinaemic hypoglycaemia of infancy: therapy, clinical outcome and mutational analysis. European Journal of Pediatrics 156 10 (1997) 754-757
24. Persaud S.J., Jones P.M., Sugden D., and Howell S.L. The role of protein kinase C in cholinergic stimulation of insulin secretion from rat islets of Langerhans. Biochemical Journal 264 3 (1989) 753-758
25. Sahai A., Fadda G.Z., and Massry S.G. Parathyroid hormone activates protein kinase C of pancreatic islets. Endocrinology 131 4 (1992) 1889-1894
26. Samols E., Bonner-Weir S., and Weir G.C. Intra-islet insulin-glucagon-somatostatin relationships. Clinical Endocrinology and Metabolism 15 1 (1986) 33-58
27. Schatz H., and Kullek U. Studies on the local (paracrine) actions of glucagon, somatostatin and insulin in isolated islets of rat pancreas. FEBS Letters 122 2 (1980) 207-210
28. Siemann E.H., and Creasy L.L. Concentration of the phytoalexin resveratrol in wine. American Journal of Enology and Viticulture 43 (1992) 49-52
29. Skak K., Gotfredsen C.F., Lundsgaard D., Hansen J.B., Sturis J., and Markholst H. Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 53 4 (2004) 1089-1095
30. Slater S.J., Seiz J.L., Cook A.C., Stagliano B.A., and Buzas C.J. Inhibition of protein kinase C by resveratrol. Biochimica et Biophysica Acta 1637 1 (2003) 59-69
31. Su H.C., Hung L.M., and Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. American Journal of Physiology: Endocrinology and Metabolism 290 6 (2006) 1339-1346
32. Surwit R.S., Dixon T.M., Petro A.E., Daniel K.W., and Collins S. Diazoxide restores beta3-adrenergic receptor function in diet-induced obesity and diabetes. Endocrinology 141 10 (2000) 3630-3637
33. Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. European Journal of Pharmacology 552 1-3 (2006) 176-181
34. Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. American Journal of Physiology: Endocrinology and Metabolism 293 4 (2007) 901-907
35. Tanaka Y., Funahashi H., Imai T., Naruse T., Suzumura K., and Oda Y. The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case. Surgery Today 30 6 (2000) 541-543
36. von Eyben F.E., Grodum E., Gjessing H.J., Hagen C., and Nielsen H. Metabolic remission with octreotide in patients with insulinoma. Journal of Internal Medicine 235 3 (1994) 245-248
37. Welt C.K., Taylor A.E., Martin K.A., and Hall J.E. Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 87 12 (2002) 5559-5565
38. Woo J.H., Lim J.H., Kim Y.H., Suh S.I., Min do S., Chang J.S., Lee Y.H., Park J.W., and Kwon T.K. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 23 10 (2004) 1845-1853
39. Zheng J., and Ramirez V.D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. British Journal of Pharmacology 130 5 (2000) 1115-1123
40. Zini R., Morin C., Bertelli A., Bertelli A.A., and Tillement J.P. Effects of resveratrol on the rat brain respiratory chain. Drugs Under Experimental and Clinical Research 25 2-3 (1999) 87-97